Somatrogon

FDA approved

Somatrogon (Ngenla) is a once-weekly growth hormone approved by the FDA in 2023 for children with growth hormone deficiency.

At a glance

Where it acts: Hormones & metabolism
Regulatory status: FDA approvedApproved by the U.S. FDA for at least one medical use.

Mechanism of Action

Somatrogon is human growth hormone fused to copies of a peptide from human chorionic gonadotropin, which adds sugar groups that slow its clearance. It activates growth hormone receptors with a weekly dose.

Typical Dosage (Research)

Prescription-only medicine. Dosing is set by a physician according to the FDA-approved label and the condition being treated.

Side Effects & Risks

Injection site reactions (pain, redness, swelling), headache, fever and anemia.

Class risks shared with other growth hormones, including raised intracranial pressure, slipped capital femoral epiphysis, scoliosis progression and effects on glucose and thyroid levels.

Who Uses Somatrogon

Children 3 years and older with growth failure due to inadequate growth hormone secretion.